| When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature P Manu, D Sarpal, O Muir, JM Kane, CU Correll Schizophrenia research 134 (2-3), 180-186, 2012 | 185 | 2012 |
| Real-world efficacy of deep TMS for obsessive-compulsive disorder: post-marketing data collected from twenty-two clinical sites Y Roth, A Tendler, MK Arikan, R Vidrine, D Kent, O Muir, C MacMillan, ... Journal of psychiatric research 137, 667-672, 2021 | 57 | 2021 |
| Blogging and social media for mental health education and advocacy: a review for psychiatrists HS Peek, M Richards, O Muir, SR Chan, M Caton, C MacMillan Current psychiatry reports 17, 1-8, 2015 | 57 | 2015 |
| Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis A Tendler, S Goerigk, S Zibman, S Ouaknine, T Harmelech, GS Pell, ... Psychiatry Research 324, 115179, 2023 | 13 | 2023 |
| Real world efficacy and safety of various accelerated deep TMS protocols for major depression Y Roth, CA Hanlon, G Pell, S Zibman, T Harmelech, OS Muir, C MacMillan, ... Psychiatry Research 328, 115482, 2023 | 8 | 2023 |
| Long-term outcomes of a course of deep TMS for treatment-resistant OCD T Harmelech, A Tendler, MK Arikan, HL Çetin, MT Esmeray, R Ilhan, ... Brain Stimulation: Basic, Translational, and Clinical Research in …, 2022 | 7 | 2022 |
| Mental health clinicians’ attitudes toward narcissistic personality disorder. O Muir, JN Weinfeld, D Ruiz, D Ostrovsky, M Fiolhais, C MacMillan Personality Disorders: Theory, Research, and Treatment 12 (5), 389, 2021 | 4 | 2021 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin BJ Tabaac, K Shinozuka, A Arenas, BD Beutler, K Cherian, VD Evans, ... American Journal of Therapeutics 31 (2), e121-e132, 2024 | 3 | 2024 |
| Attitudes of children and adolescents and their caregivers towards long-acting injectable antipsychotics in a cohort of youth initiating oral antipsychotic treatment CU Correll, O Muir, A Al-Jadiri, S Kapoor, M Carella, E Sheridan, L David, ... Neuropsychopharmacology 38, S280-S280, 2013 | 3 | 2013 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD) BD Beutler, K Shinozuka, BJ Tabaac, A Arenas, K Cherian, VD Evans, ... American Journal of Therapeutics 31 (2), e104-e111, 2024 | 2 | 2024 |
| Deep TMS for major depression, interim post-marketing analysis of 1040 patients. SA Harvey, A Tendler, M DeLuca, J Stehberg, R Naimark, D Schmidt, ... Brain Stimulation: Basic, Translational, and Clinical Research in …, 2020 | 2 | 2020 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—3, 4-Methylenedioxy-methamphetamine (MDMA) K Shinozuka, BJ Tabaac, A Arenas, BD Beutler, K Cherian, VD Evans, ... American Journal of Therapeutics 31 (2), e141-e154, 2024 | 1 | 2024 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics OS Muir, K Shinozuka, BD Beutler, A Arenas, K Cherian, VD Evans, ... American Journal of Therapeutics 31 (2), e178-e182, 2024 | 1 | 2024 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine K Cherian, K Shinozuka, BJ Tabaac, A Arenas, BD Beutler, VD Evans, ... American Journal of Therapeutics 31 (2), e133-e140, 2024 | 1 | 2024 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine VD Evans, A Arenas, K Shinozuka, BJ Tabaac, BD Beutler, K Cherian, ... American Journal of Therapeutics 31 (2), e155-e177, 2024 | 1 | 2024 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—N, N-Dimethyltryptamine and Ayahuasca K Shinozuka, BJ Tabaac, A Arenas, BD Beutler, K Cherian, VD Evans, ... American Journal of Therapeutics 31 (2), e112-e120, 2024 | 1 | 2024 |
| Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview BJ Tabaac, K Shinozuka, A Arenas, BD Beutler, K Cherian, VD Evans, ... American Journal of Therapeutics 31 (2), e97-e103, 2024 | 1 | 2024 |
| Evaluating passive physiological data collection during Spravato treatment TM Solomon, M Hajduk, M Majernik, J Jemison, A Deschamps, ... Frontiers in Digital Health 5, 1281529, 2023 | 1 | 2023 |
| Remote monitoring and AI for detecting tardive dyskinesia and improving patient outcomes. A Sterns, L Larsen, B Grimm, OS Muir Gerontechnology 21, 2022 | 1 | 2022 |
| Accelerated And Non-Accelerated dTMS Protocols Both Effective In Treatment Of MDD O Muir, D Ruiz, R Abbott-Sinclair, C MacMillan Brain Stimulation: Basic, Translational, and Clinical Research in …, 2020 | 1 | 2020 |
Christoph Correll; Christoph U CorrellProfessor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead, NY USA; Professor of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Investigator, Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research Manhasset, NY, USA在 northwell.edu 的电子邮件经过验证
